Mechanism of PERK - eIF2a Pathways in Intestinal Mucosal Barrier of IBS-D and the Role "Metabolism Ingredients" of Tongxieyaofang
- Conditions
- IBS (Irritable Bowel Syndrome)
- Interventions
- Drug: Tongxieyaofang(granule)
- Registration Number
- NCT04122586
- Brief Summary
Diarrhea irritable bowel syndrome(IBS-D）has seriously affected health and quality of life of patients.It may be important pathogenesis in development and recurrence of the process of IBS-D,excessive endoplasmic reticulum stress (ERS) activated PERK(proteinkinaseR-like ERkinase，PERK)-eIF2a(eukaryotic translation initiation factor 2 alpha,eIF2a) pathway and damaged intestinal mucosal epithelial Barrier. Tongxieyaofang(TXYF) had obtained satisfactory effect in treating IBS-D in clinic and previous study, but it is unknown that herbal formula how to work.This project applies metabolomics method to detect plasma,urine and stool metabolites for patients before and after treatment, to determine the effects of the"multiple ingredients"of TXYF in body.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 60
- Patients meeting the diagnostic criteria of Western medicine for IBS-D;
- aged 18-70 years old; with a baseline IBS-SSS score over 75 points;
- voluntarily signed the informed consent;
- local resident who could ensure follow-ups, with basic reading ability
- Patients with IBS-C, -M, and uncertain forms;
- accompanied with serious lesions in major organs including heart, liver, and kidney, hematopoietic system diseases, and tumors;
- gastrointestinal organic disease (e.g., chronic pancreatitis), or systemic diseases affecting the digestive tract motion (e.g., hyperthyroidism,diabetes, chronic renal insufficiency, and nervous system diseases);
- undergoing or requiring constant use of drugs that may affect gastrointestinal functions (e.g., anti-cholinergic drugs, calcium channel blockers, 5-HT3 receptor antagonist, antidiarrheal agents, antacids, prokinetic agents, antidepressants, anxiolytics, and intestinal flora regulating drugs);
- with history of abdominal surgery (e.g., cholecystectomy);
- with an allergy history of tested drugs or severe allergy history of food;
- pregnant and lactating female;
- with a history of neurological or psychiatric disorders;
- or participating in other clinical trial.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Tongxieyaofang granule group Tongxieyaofang(granule) -
- Primary Outcome Measures
Name Time Method Irritable Bowel Syndrome Symptom Severity(IBS-SSS) scale IBS-SSS was evaluated by patients at 4th week Patients are graded according to their own symptoms（abdominal pain，bloating，defecation satisfaction，the extent to which the disease affects the lives of patients，bowel movements）, the total score less than 75 points was considered as in remission, 75\~175 as mild, 175\~300 as moderate, and over 300 as severe. We will assess changes in patient scores before and after treatment to reflect the extent of disease remission.
Bristol stool form scale（BSFS） BSFS was evaluated by patients at 4th week Different fecal types can reflect different intestinal transit times, the lower the score, the longer the transmission time; the higher the score, the shorter the transmission time. We will assess changes in scores before and after treatment to reflect the extent of disease remission.
- Secondary Outcome Measures
Name Time Method SF-36(the MOS item short from health survey)Scale SF-36 Scale was evaluated at 4th week Score evaluation from 8 aspects: physical function, role-physical, pain, global health status, vitality，social function,role-emotional， mental health.Use score changes to assess improvement in all areas of the patient. Maximum score is147.The higher the score, the better the status in all aspects.
IBS-D PRO( patient reported outcomes) Scale IBS-D PRO Scale was evaluated at 4th week Grading from the field of physiology, independence, and psychology，Use score changes to assess improvement in all areas of the patient.Minimum score is 0，means no symptoms，maximum score is 144，means all symptoms are severe.
Trial Locations
- Locations (1)
Xiyuan hospital
🇨🇳Beijing, Beijing, China